118 related articles for article (PubMed ID: 28117434)
1. Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.
Kloth JSL; Verboom MC; Swen JJ; van der Straaten T; Sleijfer S; Reyners AKL; Steeghs N; Gelderblom H; Guchelaar HJ; Mathijssen RHJ
Pharmacogenomics J; 2018 Jan; 18(1):49-55. PubMed ID: 28117434
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
[No Abstract] [Full Text] [Related]
4. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib.
Koh Y; Lee HE; Im SA; Kim SH; Kim TM; Han SW; Oh DY; Kim JH; Lee SH; Kim DW; Kim TY; Kim WH; Heo DS; Bang YJ
Diagn Mol Pathol; 2011 Sep; 20(3):143-7. PubMed ID: 21817899
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
6. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.
Zhang X; Zhou Y; Wu X; Nie M; Zhang B; Zhou Y; Sun L; Liu Z; Liu X; Kou Y; Wang Y; Zhang Y; Hao C; Shen L; Li J
Eur J Surg Oncol; 2019 Mar; 45(3):318-323. PubMed ID: 30145000
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
9. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Ravegnini G; Nannini M; Zenesini C; Simeon V; Sammarini G; Urbini M; Gatto L; Saponara M; Biasco G; Pantaleo MA; Venturoli N; Hrelia P; Angelini S
Angiogenesis; 2017 Feb; 20(1):139-148. PubMed ID: 27896475
[TBL] [Abstract][Full Text] [Related]
10. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib.
Dudeck O; Zeile M; Reichardt P; Pink D
Ann Oncol; 2011 Aug; 22(8):1828-33. PubMed ID: 21289369
[TBL] [Abstract][Full Text] [Related]
11. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
12. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Yeh CN; Wang SY; Tsai CY; Chen YY; Liu CT; Chiang KC; Chen TW; Liu YY; Yeh TS
Int J Surg; 2017 Mar; 39():30-36. PubMed ID: 28110026
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.
Ravegnini G; Nannini M; Simeon V; Musti M; Sammarini G; Saponara M; Gatto L; Urbini M; Astolfi A; Biasco G; Pantaleo MA; Venturoli N; Hrelia P; Angelini S
Tumour Biol; 2016 Oct; 37(10):13413-13423. PubMed ID: 27460091
[TBL] [Abstract][Full Text] [Related]
14. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
15. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
16. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
[No Abstract] [Full Text] [Related]
17. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
Dong Z; Gao J; Gong J; Li J; Li Y; Shen L; Li J
Future Oncol; 2017 Oct; 13(23):2035-2043. PubMed ID: 28685593
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
19. Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.
Yang J; Ikezoe T; Nishioka C; Takezaki Y; Hanazaki K; Taguchi T; Yokoyama A
Int J Cancer; 2012 Feb; 130(4):959-66. PubMed ID: 21445973
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Angelini S; Pantaleo MA; Ravegnini G; Zenesini C; Cavrini G; Nannini M; Fumagalli E; Palassini E; Saponara M; Di Battista M; Casali PG; Hrelia P; Cantelli-Forti G; Biasco G
Pharmacol Res; 2013 Feb; 68(1):1-6. PubMed ID: 23127916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
